---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-058966"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:02:20.472594+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M

## Summary
- Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.
- Preliminary cash and equivalents as of March 31, 2025: $2.1M (unaudited, subject to change).
- Subsequent registered direct offerings on April 4 and April 22 raised approx. $1.9M and $1.8M respectively.
- Company has not finalized Q1 2025 financial results; independent auditor has not reviewed preliminary data.

## SEC filing metadata
- accession: 0000950170-25-058966
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025058966/0000950170-25-058966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025058966/apvo-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-058966
- JSON: https://secwatch.observer/filing/0000950170-25-058966.json
- Plain text: https://secwatch.observer/filing/0000950170-25-058966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.